Global Infertility Drugs Market By Drug Class (Dopamine agonists, Clomiphene (Clomid), Gonadotropins, Metformin (Glucophage), Letrozole, Bromocriptine, Others) By Gender (Men, Women) By Route of Administration (Subcutaneous, Intramuscular) By Distribution Channel (Online, Offline (Retail Pharmacies, Hospitals and Clinics, Fertility Centers, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
Global Infertility Drugs Market was Worth USD 3,480.14 Million in 2022, With an Estimated CAGR of 6.5% from 2023-2031.
Infertility drugs are medicines used to control or induce ovulation. The main form of therapy for women who are infertile because of ovulation problems is fertility medication. In order to cause ovulation, fertility medications often act similarly to natural chemicals follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Moreover, in order to attempt to induce a better egg or an additional egg or eggs in women who ovulate, infertility drugs are also utilized. According to a study it was estimated that the prevalence of infertility range from 6% to 24%, with up to 24% of couples having trouble becoming pregnant. At some time in their lives, 8% to 18% of men and 12% of women seek treatment for infertility. However, a lot of couples seeking infertility treatment have very little or no insurance coverage, and the fees could be too high for their family to bear. Thus, to overcome these challenges infertility drugs are highly getting popular across various countries which has led to the growth of the global infertility drugs market.
Global Infertility Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2031
Based on drug class, gonadotropins segment had the highest share in the global infertility drugs market in 2022. The gonads, which are the ovaries or testicles, are hormones called gonadotropins. Gonadotropins are injectable fertility medications that either include both luteinizing hormone (LH) and follicle stimulating hormone (FSH), or both. They are administered to women to aid in the body's generation of the hormones necessary for egg formation. They might potentially be used to encourage sperm production in males who have low levels of FSH and testosterone. In order to stimulate the female body to generate many eggs so that more than one may be removed and fertilised in the lab, these medications are frequently utilized when a woman is not ovulating, has low hormone levels, or is undergoing an IVF cycle. These fertility medicines are frequently sold under the brand names Follistim, Gonal-F, and Bravelle (rFSH). The hMG combo drugs go by the names Repronex and Menopur. Ovidrel or Pregnyl are the brands for human chorionic gonadotropins (hCG). Few FDA-approved outsourced pharmacies presently offer male gonadotropin medication, therefore raising awareness of these pharmacies may help patients with male hypogonadism and infertility overcome hurdles to care.
North America had the highest share in the infertility drugs market in 2022. In the last few years there has been rise in the number of cases of infertility amongst both men and women due unhealthy lifestyles and behaviors which has led to a rising concern. Due to the rising awareness about infertility drugs and their success rates, there has been a huge demand for infertility drugs. Moreover, the leading players in the market are focused on further investments into research and development for the growth of the infertility drugs market in North America.
Competitive Landscape
The report provides both, qualitative and quantitative research of global infertility drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global infertility drugs market are
- Abbott
- Cosette Pharmaceuticals
- Ferring B.V.
- LEXICARE PHARMA PVT. LTD.
- Mankind Pharma
- Merck KGaA
- Novartis AG
- Organon group of companies.
- Pfizer Inc.
- Ralington Pharma LLP
- REWINE PHARMACEUTICAL
- Sanofi
- Teva Pharmaceutical Industries LTD.
- Trumac Healthcare
- winfertility
- Other Industry Participants
Global Infertility Drugs Market
By Drug Class
- Dopamine agonists
- Clomiphene (Clomid)
- Gonadotropins
- Metformin (Glucophage)
- Letrozole
- Bromocriptine
- Others
By Gender
- Men
- Women
By Route of Administration
- Subcutaneous
- Intramuscular
By Distribution Channel
- Online
- Offline
- Retail Pharmacies
- Hospitals and Clinics
- Fertility Centers
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2022
1.2.3. Forecast Years: 2023 – 2031
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Infertility Drugs Market
6.
Market
Synopsis: Infertility Drugs Market
7.
Infertility
Drugs Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Infertility Drugs Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Infertility Drugs Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Infertility Drugs
Market
8.
Global Infertility
Drugs Market Analysis and Forecasts, 2023 – 2031
8.1. Overview
8.1.1. Global Infertility Drugs Market Revenue (US$
Mn)
8.2. Global Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Drug Class
8.2.1. Dopamine agonists
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.1.3.
Market
Forecast, 2023 – 2031
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2022
8.2.1.5.1.2. Market Forecast, 2023 – 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2022
8.2.1.5.2.2. Market Forecast, 2023 – 2031
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2022
8.2.1.5.3.2. Market Forecast, 2023 – 2031
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2022
8.2.1.5.4.2. Market Forecast, 2023 – 2031
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2022
8.2.1.5.5.2. Market Forecast, 2023 – 2031
8.2.2. Clomiphene (Clomid)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.2.3.
Market
Forecast, 2023 – 2031
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2022
8.2.2.5.1.2. Market Forecast, 2023 – 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2022
8.2.2.5.2.2. Market Forecast, 2023 – 2031
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2022
8.2.2.5.3.2. Market Forecast, 2023 – 2031
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2022
8.2.2.5.4.2. Market Forecast, 2023 – 2031
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2022
8.2.2.5.5.2. Market Forecast, 2023 – 2031
8.2.3. Gonadotropins
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.3.3.
Market
Forecast, 2023 – 2031
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2022
8.2.3.5.1.2. Market Forecast, 2023 – 2031
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2022
8.2.3.5.2.2. Market Forecast, 2023 – 2031
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2022
8.2.3.5.3.2. Market Forecast, 2023 – 2031
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2022
8.2.3.5.4.2. Market Forecast, 2023 – 2031
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2022
8.2.3.5.5.2. Market Forecast, 2023 – 2031
8.2.4. Metformin (Glucophage)
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.4.3.
Market
Forecast, 2023 – 2031
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2022
8.2.4.5.1.2. Market Forecast, 2023 – 2031
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2022
8.2.4.5.2.2. Market Forecast, 2023 – 2031
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2022
8.2.4.5.3.2. Market Forecast, 2023 – 2031
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2022
8.2.4.5.4.2. Market Forecast, 2023 – 2031
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2022
8.2.4.5.5.2. Market Forecast, 2023 – 2031
8.2.5. Letrozole
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.5.3.
Market
Forecast, 2023 – 2031
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2022
8.2.5.5.1.2. Market Forecast, 2023 – 2031
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2022
8.2.5.5.2.2. Market Forecast, 2023 – 2031
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2022
8.2.5.5.3.2. Market Forecast, 2023 – 2031
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2022
8.2.5.5.4.2. Market Forecast, 2023 – 2031
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2022
8.2.5.5.5.2. Market Forecast, 2023 – 2031
8.2.6. Bromocriptine
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.6.3.
Market
Forecast, 2023 – 2031
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2022
8.2.6.5.1.2. Market Forecast, 2023 – 2031
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2022
8.2.6.5.2.2. Market Forecast, 2023 – 2031
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2022
8.2.6.5.3.2. Market Forecast, 2023 – 2031
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2022
8.2.6.5.4.2. Market Forecast, 2023 – 2031
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2022
8.2.6.5.5.2. Market Forecast, 2023 – 2031
8.2.7. Others
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.7.3.
Market
Forecast, 2023 – 2031
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1.
North
America
8.2.7.5.1.1. Market Estimation, 2015 - 2022
8.2.7.5.1.2. Market Forecast, 2023 – 2031
8.2.7.5.2.
Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2022
8.2.7.5.2.2. Market Forecast, 2023 – 2031
8.2.7.5.3.
Asia
Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2022
8.2.7.5.3.2. Market Forecast, 2023 – 2031
8.2.7.5.4.
Middle
East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2022
8.2.7.5.4.2. Market Forecast, 2023 – 2031
8.2.7.5.5.
Latin
America
8.2.7.5.5.1. Market Estimation, 2015 - 2022
8.2.7.5.5.2. Market Forecast, 2023 – 2031
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Class
9.
Global Infertility
Drugs Market Analysis and Forecasts, 2023 – 2031
9.1. Overview
9.2. Global Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Gender
9.2.1. Men
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.1.3.
Market
Forecast, 2023 – 2031
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2022
9.2.1.5.1.2. Market Forecast, 2023 – 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2022
9.2.1.5.2.2. Market Forecast, 2023 – 2031
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2022
9.2.1.5.3.2. Market Forecast, 2023 – 2031
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2022
9.2.1.5.4.2. Market Forecast, 2023 – 2031
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2022
9.2.1.5.5.2. Market Forecast, 2023 – 2031
9.2.2. Women
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.2.3.
Market
Forecast, 2023 – 2031
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2022
9.2.2.5.1.2. Market Forecast, 2023 – 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2022
9.2.2.5.2.2. Market Forecast, 2023 – 2031
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2022
9.2.2.5.3.2. Market Forecast, 2023 – 2031
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2022
9.2.2.5.4.2. Market Forecast, 2023 – 2031
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2022
9.2.2.5.5.2. Market Forecast, 2023 – 2031
9.3. Key Segment for Channeling Investments
9.3.1. By Gender
10. Global Infertility Drugs Market Analysis and
Forecasts, 2023 – 2031
10.1. Overview
10.2. Global Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Route of Administration
10.2.1. Subcutaneous
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.1.3.
Market
Forecast, 2023 – 2031
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2022
10.2.1.5.1.2. Market Forecast, 2023 – 2031
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2022
10.2.1.5.2.2. Market Forecast, 2023 – 2031
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2022
10.2.1.5.3.2. Market Forecast, 2023 – 2031
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2022
10.2.1.5.4.2. Market Forecast, 2023 – 2031
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2022
10.2.1.5.5.2. Market Forecast, 2023 – 2031
10.2.2. Intramuscular
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.2.3.
Market
Forecast, 2023 – 2031
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2022
10.2.2.5.1.2. Market Forecast, 2023 – 2031
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2022
10.2.2.5.2.2. Market Forecast, 2023 – 2031
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2022
10.2.2.5.3.2. Market Forecast, 2023 – 2031
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2022
10.2.2.5.4.2. Market Forecast, 2023 – 2031
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2022
10.2.2.5.5.2. Market Forecast, 2023 – 2031
10.3. Key Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Infertility Drugs Market Analysis and
Forecasts, 2023 – 2031
11.1. Overview
11.2. Global Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
11.2.1. Online
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.1.3.
Market
Forecast, 2023 – 2031
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2022
11.2.1.5.1.2. Market Forecast, 2023 – 2031
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2022
11.2.1.5.2.2. Market Forecast, 2023 – 2031
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2022
11.2.1.5.3.2. Market Forecast, 2023 – 2031
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2022
11.2.1.5.4.2. Market Forecast, 2023 – 2031
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2022
11.2.1.5.5.2. Market Forecast, 2023 – 2031
11.2.2. Offline
(Definition, Market Estimation and Penetration, 2015 - 2022, Market
Estimation (2015 - 2022), Market Forecast (2023 – 2031), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Retail Pharmacies ,
Hospitals and Clinics , Fertility Centers , Others )
11.2.2.1.
Retail
Pharmacies
11.2.2.2.
Hospitals
and Clinics
11.2.2.3.
Fertility
Centers
11.2.2.4.
Others
11.3. Key Segment for Channeling Investments
11.3.1. By Distribution Channel
12. North America Infertility Drugs Market
Analysis and Forecasts, 2023 – 2031
12.1. Overview
12.1.1. North America Infertility Drugs Market
Revenue (US$ Mn)
12.2. North America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Drug Class
12.2.1. Dopamine agonists
12.2.2. Clomiphene (Clomid)
12.2.3. Gonadotropins
12.2.4. Metformin (Glucophage)
12.2.5. Letrozole
12.2.6. Bromocriptine
12.2.7. Others
12.3. North America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Gender
12.3.1. Men
12.3.2. Women
12.4. North America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.4.1. Subcutaneous
12.4.2. Intramuscular
12.5. North America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.1. Online
12.5.2. Offline
12.5.2.1.
Retail
Pharmacies
12.5.2.2.
Hospitals
and Clinics
12.5.2.3.
Fertility
Centers
12.5.2.4.
Others
12.6. North America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.1.1.1.
Dopamine
agonists
12.6.1.1.2.
Clomiphene
(Clomid)
12.6.1.1.3.
Gonadotropins
12.6.1.1.4.
Metformin
(Glucophage)
12.6.1.1.5.
Letrozole
12.6.1.1.6.
Bromocriptine
12.6.1.1.7.
Others
12.6.1.2.
U.S Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
12.6.1.2.1.
Men
12.6.1.2.2.
Women
12.6.1.3.
U.S Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.1.3.1.
Subcutaneous
12.6.1.3.2.
Intramuscular
12.6.1.4.
U.S Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.1.4.1.
Online
12.6.1.4.2.
Offline
12.6.1.4.2.1. Retail Pharmacies
12.6.1.4.2.2. Hospitals and Clinics
12.6.1.4.2.3. Fertility Centers
12.6.1.4.2.4. Others
12.6.2. Canada
12.6.2.1.
Canada Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.2.1.1.
Dopamine
agonists
12.6.2.1.2.
Clomiphene
(Clomid)
12.6.2.1.3.
Gonadotropins
12.6.2.1.4.
Metformin
(Glucophage)
12.6.2.1.5.
Letrozole
12.6.2.1.6.
Bromocriptine
12.6.2.1.7.
Others
12.6.2.2.
Canada Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
12.6.2.2.1.
Men
12.6.2.2.2.
Women
12.6.2.3.
Canada Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.2.3.1.
Subcutaneous
12.6.2.3.2.
Intramuscular
12.6.2.4.
Canada Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.2.4.1.
Online
12.6.2.4.2.
Offline
12.6.2.4.2.1. Retail Pharmacies
12.6.2.4.2.2. Hospitals and Clinics
12.6.2.4.2.3. Fertility Centers
12.6.2.4.2.4. Others
12.6.3. Mexico
12.6.3.1.
Mexico Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.3.1.1.
Dopamine
agonists
12.6.3.1.2.
Clomiphene
(Clomid)
12.6.3.1.3.
Gonadotropins
12.6.3.1.4.
Metformin
(Glucophage)
12.6.3.1.5.
Letrozole
12.6.3.1.6.
Bromocriptine
12.6.3.1.7.
Others
12.6.3.2.
Mexico Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
12.6.3.2.1.
Men
12.6.3.2.2.
Women
12.6.3.3.
Mexico Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.3.3.1.
Subcutaneous
12.6.3.3.2.
Intramuscular
12.6.3.4.
Mexico Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.3.4.1.
Online
12.6.3.4.2.
Offline
12.6.3.4.2.1. Retail Pharmacies
12.6.3.4.2.2. Hospitals and Clinics
12.6.3.4.2.3. Fertility Centers
12.6.3.4.2.4. Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.6.4.1.1.
Dopamine
agonists
12.6.4.1.2.
Clomiphene
(Clomid)
12.6.4.1.3.
Gonadotropins
12.6.4.1.4.
Metformin
(Glucophage)
12.6.4.1.5.
Letrozole
12.6.4.1.6.
Bromocriptine
12.6.4.1.7.
Others
12.6.4.2.
Rest of
North America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Gender
12.6.4.2.1.
Men
12.6.4.2.2.
Women
12.6.4.3.
Rest of
North America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.6.4.3.1.
Subcutaneous
12.6.4.3.2.
Intramuscular
12.6.4.4.
Rest of
North America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.4.4.1.
Online
12.6.4.4.2.
Offline
12.6.4.4.2.1. Retail Pharmacies
12.6.4.4.2.2. Hospitals and Clinics
12.6.4.4.2.3. Fertility Centers
12.6.4.4.2.4. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Drug Class
12.7.3. By Gender
12.7.4. By Route of Administration
12.7.5. By Distribution Channel
13. Europe Infertility Drugs Market Analysis and
Forecasts, 2023 – 2031
13.1. Overview
13.1.1. Europe Infertility Drugs Market Revenue (US$
Mn)
13.2. Europe Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.2.1. Dopamine agonists
13.2.2. Clomiphene (Clomid)
13.2.3. Gonadotropins
13.2.4. Metformin (Glucophage)
13.2.5. Letrozole
13.2.6. Bromocriptine
13.2.7. Others
13.3. Europe Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Gender
13.3.1. Men
13.3.2. Women
13.4. Europe Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.4.1. Subcutaneous
13.4.2. Intramuscular
13.5. Europe Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.5.1. Online
13.5.2. Offline
13.5.2.1.
Retail
Pharmacies
13.5.2.2.
Hospitals
and Clinics
13.5.2.3.
Fertility
Centers
13.5.2.4.
Others
13.6. Europe Infertility Drugs Market Revenue (US$
Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.1.1.1.
Dopamine
agonists
13.6.1.1.2.
Clomiphene
(Clomid)
13.6.1.1.3.
Gonadotropins
13.6.1.1.4.
Metformin
(Glucophage)
13.6.1.1.5.
Letrozole
13.6.1.1.6.
Bromocriptine
13.6.1.1.7.
Others
13.6.1.2.
France Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.1.2.1.
Men
13.6.1.2.2.
Women
13.6.1.3.
France Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.1.3.1.
Subcutaneous
13.6.1.3.2.
Intramuscular
13.6.1.4.
France Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.1.4.1.
Online
13.6.1.4.2.
Offline
13.6.1.4.2.1. Retail Pharmacies
13.6.1.4.2.2. Hospitals and Clinics
13.6.1.4.2.3. Fertility Centers
13.6.1.4.2.4. Others
13.6.2. The UK
13.6.2.1.
The UK Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.2.1.1.
Dopamine
agonists
13.6.2.1.2.
Clomiphene
(Clomid)
13.6.2.1.3.
Gonadotropins
13.6.2.1.4.
Metformin
(Glucophage)
13.6.2.1.5.
Letrozole
13.6.2.1.6.
Bromocriptine
13.6.2.1.7.
Others
13.6.2.2.
The UK Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.2.2.1.
Men
13.6.2.2.2.
Women
13.6.2.3.
The UK Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.2.3.1.
Subcutaneous
13.6.2.3.2.
Intramuscular
13.6.2.4.
The UK Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.2.4.1.
Online
13.6.2.4.2.
Offline
13.6.2.4.2.1. Retail Pharmacies
13.6.2.4.2.2. Hospitals and Clinics
13.6.2.4.2.3. Fertility Centers
13.6.2.4.2.4. Others
13.6.3. Spain
13.6.3.1.
Spain Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.3.1.1.
Dopamine
agonists
13.6.3.1.2.
Clomiphene
(Clomid)
13.6.3.1.3.
Gonadotropins
13.6.3.1.4.
Metformin
(Glucophage)
13.6.3.1.5.
Letrozole
13.6.3.1.6.
Bromocriptine
13.6.3.1.7.
Others
13.6.3.2.
Spain Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.3.2.1.
Men
13.6.3.2.2.
Women
13.6.3.3.
Spain Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.3.3.1.
Subcutaneous
13.6.3.3.2.
Intramuscular
13.6.3.4.
Spain Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.3.4.1.
Online
13.6.3.4.2.
Offline
13.6.3.4.2.1. Retail Pharmacies
13.6.3.4.2.2. Hospitals and Clinics
13.6.3.4.2.3. Fertility Centers
13.6.3.4.2.4. Others
13.6.4. Germany
13.6.4.1.
Germany Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.4.1.1.
Dopamine
agonists
13.6.4.1.2.
Clomiphene
(Clomid)
13.6.4.1.3.
Gonadotropins
13.6.4.1.4.
Metformin
(Glucophage)
13.6.4.1.5.
Letrozole
13.6.4.1.6.
Bromocriptine
13.6.4.1.7.
Others
13.6.4.2.
Germany Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.4.2.1.
Men
13.6.4.2.2.
Women
13.6.4.3.
Germany Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.4.3.1.
Subcutaneous
13.6.4.3.2.
Intramuscular
13.6.4.4.
Germany Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.4.4.1.
Online
13.6.4.4.2.
Offline
13.6.4.4.2.1. Retail Pharmacies
13.6.4.4.2.2. Hospitals and Clinics
13.6.4.4.2.3. Fertility Centers
13.6.4.4.2.4. Others
13.6.5. Italy
13.6.5.1.
Italy Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.5.1.1.
Dopamine
agonists
13.6.5.1.2.
Clomiphene
(Clomid)
13.6.5.1.3.
Gonadotropins
13.6.5.1.4.
Metformin
(Glucophage)
13.6.5.1.5.
Letrozole
13.6.5.1.6.
Bromocriptine
13.6.5.1.7.
Others
13.6.5.2.
Italy Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.5.2.1.
Men
13.6.5.2.2.
Women
13.6.5.3.
Italy Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.5.3.1.
Subcutaneous
13.6.5.3.2.
Intramuscular
13.6.5.4.
Italy Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.5.4.1.
Online
13.6.5.4.2.
Offline
13.6.5.4.2.1. Retail Pharmacies
13.6.5.4.2.2. Hospitals and Clinics
13.6.5.4.2.3. Fertility Centers
13.6.5.4.2.4. Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.6.6.1.1.
Dopamine
agonists
13.6.6.1.2.
Clomiphene
(Clomid)
13.6.6.1.3.
Gonadotropins
13.6.6.1.4.
Metformin
(Glucophage)
13.6.6.1.5.
Letrozole
13.6.6.1.6.
Bromocriptine
13.6.6.1.7.
Others
13.6.6.2.
Nordic
Countries Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.6.2.1.
Men
13.6.6.2.2.
Women
13.6.6.3.
Nordic
Countries Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.6.3.1.
Subcutaneous
13.6.6.3.2.
Intramuscular
13.6.6.4.
Nordic
Countries Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.6.4.1.
Online
13.6.6.4.2.
Offline
13.6.6.4.2.1. Retail Pharmacies
13.6.6.4.2.2. Hospitals and Clinics
13.6.6.4.2.3. Fertility Centers
13.6.6.4.2.4. Others
13.6.6.5.
Nordic
Countries Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.7.1.1.
Dopamine
agonists
13.6.7.1.2.
Clomiphene
(Clomid)
13.6.7.1.3.
Gonadotropins
13.6.7.1.4.
Metformin
(Glucophage)
13.6.7.1.5.
Letrozole
13.6.7.1.6.
Bromocriptine
13.6.7.1.7.
Others
13.6.7.2.
Benelux
Union Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.7.2.1.
Men
13.6.7.2.2.
Women
13.6.7.3.
Benelux
Union Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.7.3.1.
Subcutaneous
13.6.7.3.2.
Intramuscular
13.6.7.4.
Benelux
Union Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.6.7.4.1.
Online
13.6.7.4.2.
Offline
13.6.7.4.2.1. Retail Pharmacies
13.6.7.4.2.2. Hospitals and Clinics
13.6.7.4.2.3. Fertility Centers
13.6.7.4.2.4. Others
13.6.7.5.
Benelux
Union Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.8.1.1.
Dopamine
agonists
13.6.8.1.2.
Clomiphene
(Clomid)
13.6.8.1.3.
Gonadotropins
13.6.8.1.4.
Metformin
(Glucophage)
13.6.8.1.5.
Letrozole
13.6.8.1.6.
Bromocriptine
13.6.8.1.7.
Others
13.6.8.2.
Rest of
Europe Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
13.6.8.2.1.
Men
13.6.8.2.2.
Women
13.6.8.3.
Rest of
Europe Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.8.3.1.
Subcutaneous
13.6.8.3.2.
Intramuscular
13.6.8.4.
Rest of
Europe Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.6.8.4.1.
Online
13.6.8.4.2.
Offline
13.6.8.4.2.1. Retail Pharmacies
13.6.8.4.2.2. Hospitals and Clinics
13.6.8.4.2.3. Fertility Centers
13.6.8.4.2.4. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Drug Class
13.7.3. By Gender
13.7.4. By Route of Administration
13.7.5. By Distribution Channel
14. Asia Pacific Infertility Drugs Market
Analysis and Forecasts, 2023 – 2031
14.1. Overview
14.1.1. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn)
14.2. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn) and Forecasts, By Drug Class
14.2.1. Dopamine agonists
14.2.2. Clomiphene (Clomid)
14.2.3. Gonadotropins
14.2.4. Metformin (Glucophage)
14.2.5. Letrozole
14.2.6. Bromocriptine
14.2.7. Others
14.3. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn) and Forecasts, By Gender
14.3.1. Men
14.3.2. Women
14.4. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.4.1. Subcutaneous
14.4.2. Intramuscular
14.5. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.5.1. Online
14.5.2. Offline
14.5.2.1.
Retail
Pharmacies
14.5.2.2.
Hospitals
and Clinics
14.5.2.3.
Fertility
Centers
14.5.2.4.
Others
14.6. Asia Pacific Infertility Drugs Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.1.1.1.
Dopamine
agonists
14.6.1.1.2.
Clomiphene
(Clomid)
14.6.1.1.3.
Gonadotropins
14.6.1.1.4.
Metformin
(Glucophage)
14.6.1.1.5.
Letrozole
14.6.1.1.6.
Bromocriptine
14.6.1.1.7.
Others
14.6.1.2.
China Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.1.2.1.
Men
14.6.1.2.2.
Women
14.6.1.3.
China Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.1.3.1.
Subcutaneous
14.6.1.3.2.
Intramuscular
14.6.1.4.
China Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.1.4.1.
Online
14.6.1.4.2.
Offline
14.6.1.4.2.1. Retail Pharmacies
14.6.1.4.2.2. Hospitals and Clinics
14.6.1.4.2.3. Fertility Centers
14.6.1.4.2.4. Others
14.6.2. Japan
14.6.2.1.
Japan Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.2.1.1.
Dopamine
agonists
14.6.2.1.2.
Clomiphene
(Clomid)
14.6.2.1.3.
Gonadotropins
14.6.2.1.4.
Metformin
(Glucophage)
14.6.2.1.5.
Letrozole
14.6.2.1.6.
Bromocriptine
14.6.2.1.7.
Others
14.6.2.2.
Japan Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.2.2.1.
Men
14.6.2.2.2.
Women
14.6.2.3.
Japan Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.2.3.1.
Subcutaneous
14.6.2.3.2.
Intramuscular
14.6.2.4.
Japan Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.2.4.1.
Online
14.6.2.4.2.
Offline
14.6.2.4.2.1. Retail Pharmacies
14.6.2.4.2.2. Hospitals and Clinics
14.6.2.4.2.3. Fertility Centers
14.6.2.4.2.4. Others
14.6.3. India
14.6.3.1.
India Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.3.1.1.
Dopamine
agonists
14.6.3.1.2.
Clomiphene
(Clomid)
14.6.3.1.3.
Gonadotropins
14.6.3.1.4.
Metformin
(Glucophage)
14.6.3.1.5.
Letrozole
14.6.3.1.6.
Bromocriptine
14.6.3.1.7.
Others
14.6.3.2.
India Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.3.2.1.
Men
14.6.3.2.2.
Women
14.6.3.3.
India Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.3.3.1.
Subcutaneous
14.6.3.3.2.
Intramuscular
14.6.3.4.
India Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.3.4.1.
Online
14.6.3.4.2.
Offline
14.6.3.4.2.1. Retail Pharmacies
14.6.3.4.2.2. Hospitals and Clinics
14.6.3.4.2.3. Fertility Centers
14.6.3.4.2.4. Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.4.1.1.
Dopamine
agonists
14.6.4.1.2.
Clomiphene
(Clomid)
14.6.4.1.3.
Gonadotropins
14.6.4.1.4.
Metformin
(Glucophage)
14.6.4.1.5.
Letrozole
14.6.4.1.6.
Bromocriptine
14.6.4.1.7.
Others
14.6.4.2.
New
Zealand Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.4.2.1.
Men
14.6.4.2.2.
Women
14.6.4.3.
New
Zealand Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.4.3.1.
Subcutaneous
14.6.4.3.2.
Intramuscular
14.6.4.4.
New
Zealand Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.4.4.1.
Online
14.6.4.4.2.
Offline
14.6.4.4.2.1. Retail Pharmacies
14.6.4.4.2.2. Hospitals and Clinics
14.6.4.4.2.3. Fertility Centers
14.6.4.4.2.4. Others
14.6.5. Australia
14.6.5.1.
Australia
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.5.1.1.
Dopamine
agonists
14.6.5.1.2.
Clomiphene
(Clomid)
14.6.5.1.3.
Gonadotropins
14.6.5.1.4.
Metformin
(Glucophage)
14.6.5.1.5.
Letrozole
14.6.5.1.6.
Bromocriptine
14.6.5.1.7.
Others
14.6.5.2.
Australia
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.5.2.1.
Men
14.6.5.2.2.
Women
14.6.5.3.
Australia
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.5.3.1.
Subcutaneous
14.6.5.3.2.
Intramuscular
14.6.5.4.
Australia
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.5.4.1.
Online
14.6.5.4.2.
Offline
14.6.5.4.2.1. Retail Pharmacies
14.6.5.4.2.2. Hospitals and Clinics
14.6.5.4.2.3. Fertility Centers
14.6.5.4.2.4. Others
14.6.6. South Korea
14.6.6.1.
South
Korea Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.6.1.1.
Dopamine
agonists
14.6.6.1.2.
Clomiphene
(Clomid)
14.6.6.1.3.
Gonadotropins
14.6.6.1.4.
Metformin
(Glucophage)
14.6.6.1.5.
Letrozole
14.6.6.1.6.
Bromocriptine
14.6.6.1.7.
Others
14.6.6.2.
South
Korea Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.6.2.1.
Men
14.6.6.2.2.
Women
14.6.6.3.
South
Korea Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.6.3.1.
Subcutaneous
14.6.6.3.2.
Intramuscular
14.6.6.4.
South
Korea Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.6.4.1.
Online
14.6.6.4.2.
Offline
14.6.6.4.2.1. Retail Pharmacies
14.6.6.4.2.2. Hospitals and Clinics
14.6.6.4.2.3. Fertility Centers
14.6.6.4.2.4. Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.7.1.1.
Dopamine
agonists
14.6.7.1.2.
Clomiphene
(Clomid)
14.6.7.1.3.
Gonadotropins
14.6.7.1.4.
Metformin
(Glucophage)
14.6.7.1.5.
Letrozole
14.6.7.1.6.
Bromocriptine
14.6.7.1.7.
Others
14.6.7.2.
Southeast
Asia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.7.2.1.
Men
14.6.7.2.2.
Women
14.6.7.3.
Southeast
Asia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.7.3.1.
Subcutaneous
14.6.7.3.2.
Intramuscular
14.6.7.4.
Southeast
Asia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.7.4.1.
Online
14.6.7.4.2.
Offline
14.6.7.4.2.1. Retail Pharmacies
14.6.7.4.2.2. Hospitals and Clinics
14.6.7.4.2.3. Fertility Centers
14.6.7.4.2.4. Others
14.6.7.5.
Southeast
Asia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.8.1.1.
Dopamine
agonists
14.6.8.1.2.
Clomiphene
(Clomid)
14.6.8.1.3.
Gonadotropins
14.6.8.1.4.
Metformin
(Glucophage)
14.6.8.1.5.
Letrozole
14.6.8.1.6.
Bromocriptine
14.6.8.1.7.
Others
14.6.8.2.
Rest of
Asia Pacific Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
14.6.8.2.1.
Men
14.6.8.2.2.
Women
14.6.8.3.
Rest of
Asia Pacific Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.6.8.3.1.
Subcutaneous
14.6.8.3.2.
Intramuscular
14.6.8.4.
Rest of
Asia Pacific Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.8.4.1.
Online
14.6.8.4.2.
Offline
14.6.8.4.2.1. Retail Pharmacies
14.6.8.4.2.2. Hospitals and Clinics
14.6.8.4.2.3. Fertility Centers
14.6.8.4.2.4. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Drug Class
14.7.3. By Gender
14.7.4. By Route of Administration
14.7.5. By Distribution Channel
15. Middle East and Africa Infertility Drugs
Market Analysis and Forecasts, 2023 – 2031
15.1. Overview
15.1.1. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn)
15.2. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.2.1. Dopamine agonists
15.2.2. Clomiphene (Clomid)
15.2.3. Gonadotropins
15.2.4. Metformin (Glucophage)
15.2.5. Letrozole
15.2.6. Bromocriptine
15.2.7. Others
15.3. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn) and Forecasts, By Gender
15.3.1. Men
15.3.2. Women
15.4. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.4.1. Subcutaneous
15.4.2. Intramuscular
15.5. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.1. Online
15.5.2. Offline
15.5.2.1.
Retail
Pharmacies
15.5.2.2.
Hospitals
and Clinics
15.5.2.3.
Fertility
Centers
15.5.2.4.
Others
15.6. Middle East and Africa Infertility Drugs
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.1.1.1.
Dopamine
agonists
15.6.1.1.2.
Clomiphene
(Clomid)
15.6.1.1.3.
Gonadotropins
15.6.1.1.4.
Metformin
(Glucophage)
15.6.1.1.5.
Letrozole
15.6.1.1.6.
Bromocriptine
15.6.1.1.7.
Others
15.6.1.2.
Saudi
Arabia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
15.6.1.2.1.
Men
15.6.1.2.2.
Women
15.6.1.3.
Saudi
Arabia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.6.1.3.1.
Subcutaneous
15.6.1.3.2.
Intramuscular
15.6.1.4.
Saudi
Arabia Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.6.1.4.1.
Online
15.6.1.4.2.
Offline
15.6.1.4.2.1. Retail Pharmacies
15.6.1.4.2.2. Hospitals and Clinics
15.6.1.4.2.3. Fertility Centers
15.6.1.4.2.4. Others
15.6.2. UAE
15.6.2.1.
UAE Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.2.1.1.
Dopamine
agonists
15.6.2.1.2.
Clomiphene
(Clomid)
15.6.2.1.3.
Gonadotropins
15.6.2.1.4.
Metformin
(Glucophage)
15.6.2.1.5.
Letrozole
15.6.2.1.6.
Bromocriptine
15.6.2.1.7.
Others
15.6.2.2.
UAE Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
15.6.2.2.1.
Men
15.6.2.2.2.
Women
15.6.2.3.
UAE Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.2.3.1.
Subcutaneous
15.6.2.3.2.
Intramuscular
15.6.2.4.
UAE Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.2.4.1.
Online
15.6.2.4.2.
Offline
15.6.2.4.2.1. Retail Pharmacies
15.6.2.4.2.2. Hospitals and Clinics
15.6.2.4.2.3. Fertility Centers
15.6.2.4.2.4. Others
15.6.3. Egypt
15.6.3.1.
Egypt Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.3.1.1.
Dopamine
agonists
15.6.3.1.2.
Clomiphene
(Clomid)
15.6.3.1.3.
Gonadotropins
15.6.3.1.4.
Metformin
(Glucophage)
15.6.3.1.5.
Letrozole
15.6.3.1.6.
Bromocriptine
15.6.3.1.7.
Others
15.6.3.2.
Egypt Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
15.6.3.2.1.
Men
15.6.3.2.2.
Women
15.6.3.3.
Egypt Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.3.3.1.
Subcutaneous
15.6.3.3.2.
Intramuscular
15.6.3.4.
Egypt Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.3.4.1.
Online
15.6.3.4.2.
Offline
15.6.3.4.2.1. Retail Pharmacies
15.6.3.4.2.2. Hospitals and Clinics
15.6.3.4.2.3. Fertility Centers
15.6.3.4.2.4. Others
15.6.4. Kuwait
15.6.4.1.
Kuwait Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.4.1.1.
Dopamine
agonists
15.6.4.1.2.
Clomiphene
(Clomid)
15.6.4.1.3.
Gonadotropins
15.6.4.1.4.
Metformin
(Glucophage)
15.6.4.1.5.
Letrozole
15.6.4.1.6.
Bromocriptine
15.6.4.1.7.
Others
15.6.4.2.
Kuwait Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
15.6.4.2.1.
Men
15.6.4.2.2.
Women
15.6.4.3.
Kuwait Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.4.3.1.
Subcutaneous
15.6.4.3.2.
Intramuscular
15.6.4.4.
Kuwait Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.4.4.1.
Online
15.6.4.4.2.
Offline
15.6.4.4.2.1. Retail Pharmacies
15.6.4.4.2.2. Hospitals and Clinics
15.6.4.4.2.3. Fertility Centers
15.6.4.4.2.4. Others
15.6.5. South Africa
15.6.5.1.
South
Africa Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.5.1.1.
Dopamine
agonists
15.6.5.1.2.
Clomiphene
(Clomid)
15.6.5.1.3.
Gonadotropins
15.6.5.1.4.
Metformin
(Glucophage)
15.6.5.1.5.
Letrozole
15.6.5.1.6.
Bromocriptine
15.6.5.1.7.
Others
15.6.5.2.
South
Africa Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
15.6.5.2.1.
Men
15.6.5.2.2.
Women
15.6.5.3.
South
Africa Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.6.5.3.1.
Subcutaneous
15.6.5.3.2.
Intramuscular
15.6.5.4.
South
Africa Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.6.5.4.1.
Online
15.6.5.4.2.
Offline
15.6.5.4.2.1. Retail Pharmacies
15.6.5.4.2.2. Hospitals and Clinics
15.6.5.4.2.3. Fertility Centers
15.6.5.4.2.4. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Infertility Drugs Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.6.6.1.1.
Dopamine
agonists
15.6.6.1.2.
Clomiphene
(Clomid)
15.6.6.1.3.
Gonadotropins
15.6.6.1.4.
Metformin
(Glucophage)
15.6.6.1.5.
Letrozole
15.6.6.1.6.
Bromocriptine
15.6.6.1.7.
Others
15.6.6.2.
Rest of
Middle East & Africa Infertility Drugs Market Revenue (US$ Mn) and
Forecasts, By Gender
15.6.6.2.1.
Men
15.6.6.2.2.
Women
15.6.6.3.
Rest of
Middle East & Africa Infertility Drugs Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.6.3.1.
Subcutaneous
15.6.6.3.2.
Intramuscular
15.6.6.4.
Rest of
Middle East & Africa Infertility Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.6.4.1.
Online
15.6.6.4.2.
Offline
15.6.6.4.2.1. Retail Pharmacies
15.6.6.4.2.2. Hospitals and Clinics
15.6.6.4.2.3. Fertility Centers
15.6.6.4.2.4. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Drug Class
15.7.3. By Gender
15.7.4. By Route of Administration
15.7.5. By Distribution Channel
16. Latin America Infertility Drugs Market
Analysis and Forecasts, 2023 – 2031
16.1. Overview
16.1.1. Latin America Infertility Drugs Market
Revenue (US$ Mn)
16.2. Latin America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Drug Class
16.2.1. Dopamine agonists
16.2.2. Clomiphene (Clomid)
16.2.3. Gonadotropins
16.2.4. Metformin (Glucophage)
16.2.5. Letrozole
16.2.6. Bromocriptine
16.2.7. Others
16.3. Latin America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Gender
16.3.1. Men
16.3.2. Women
16.4. Latin America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.4.1. Subcutaneous
16.4.2. Intramuscular
16.5. Latin America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.5.1. Online
16.5.2. Offline
16.5.2.1.
Retail
Pharmacies
16.5.2.2.
Hospitals
and Clinics
16.5.2.3.
Fertility
Centers
16.5.2.4.
Others
16.6. Latin America Infertility Drugs Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.6.1.1.1.
Dopamine
agonists
16.6.1.1.2.
Clomiphene
(Clomid)
16.6.1.1.3.
Gonadotropins
16.6.1.1.4.
Metformin
(Glucophage)
16.6.1.1.5.
Letrozole
16.6.1.1.6.
Bromocriptine
16.6.1.1.7.
Others
16.6.1.2.
Brazil Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
16.6.1.2.1.
Men
16.6.1.2.2.
Women
16.6.1.3.
Brazil Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.1.3.1.
Subcutaneous
16.6.1.3.2.
Intramuscular
16.6.1.4.
Brazil Infertility
Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.1.4.1.
Online
16.6.1.4.2.
Offline
16.6.1.4.2.1. Retail Pharmacies
16.6.1.4.2.2. Hospitals and Clinics
16.6.1.4.2.3. Fertility Centers
16.6.1.4.2.4. Others
16.6.2. Argentina
16.6.2.1.
Argentina
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.6.2.1.1.
Dopamine
agonists
16.6.2.1.2.
Clomiphene
(Clomid)
16.6.2.1.3.
Gonadotropins
16.6.2.1.4.
Metformin
(Glucophage)
16.6.2.1.5.
Letrozole
16.6.2.1.6.
Bromocriptine
16.6.2.1.7.
Others
16.6.2.2.
Argentina
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Gender
16.6.2.2.1.
Men
16.6.2.2.2.
Women
16.6.2.3.
Argentina
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.6.2.3.1.
Subcutaneous
16.6.2.3.2.
Intramuscular
16.6.2.4.
Argentina
Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
16.6.2.4.1.
Online
16.6.2.4.2.
Offline
16.6.2.4.2.1. Retail Pharmacies
16.6.2.4.2.2. Hospitals and Clinics
16.6.2.4.2.3. Fertility Centers
16.6.2.4.2.4. Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.6.3.1.1.
Dopamine
agonists
16.6.3.1.2.
Clomiphene
(Clomid)
16.6.3.1.3.
Gonadotropins
16.6.3.1.4.
Metformin
(Glucophage)
16.6.3.1.5.
Letrozole
16.6.3.1.6.
Bromocriptine
16.6.3.1.7.
Others
16.6.3.2.
Rest of
Latin America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Gender
16.6.3.2.1.
Men
16.6.3.2.2.
Women
16.6.3.3.
Rest of
Latin America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.6.3.3.1.
Subcutaneous
16.6.3.3.2.
Intramuscular
16.6.3.4.
Rest of
Latin America Infertility Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.3.4.1.
Online
16.6.3.4.2.
Offline
16.6.3.4.2.1. Retail Pharmacies
16.6.3.4.2.2. Hospitals and Clinics
16.6.3.4.2.3. Fertility Centers
16.6.3.4.2.4. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Drug Class
16.7.3. By Gender
16.7.4. By Route of Administration
16.7.5. By Distribution Channel
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2022
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Abbott
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Cosette Pharmaceuticals
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Ferring B.V.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. LEXICARE PHARMA PVT. LTD.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Mankind Pharma
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Merck KGaA
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Novartis AG
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Organon group of companies.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Pfizer Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Ralington Pharma LLP
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. REWINE PHARMACEUTICAL
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Sanofi
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Teva Pharmaceutical Industries LTD.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Trumac Healthcare
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. winfertility
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.